Pharmaceuticals

A new platform is launching to connect pharma companies directly with 70+ global regulators, promising to slash approval times and speed patient access.

With positive safety data for its novel UC drug, a €530M cash reserve, and a new commercial chief, Abivax is poised for a major market entry.

A new Phase 2 trial is testing an inhaled version of a key IPF drug, aiming to reduce severe side effects and transform treatment for the fatal lung disease.

Wilmington PharmaTech is doubling its API capacity, a key move to bolster the U.S. drug supply chain and reduce reliance on foreign manufacturing.

Following a record year, Knight Therapeutics is doubling its share repurchase plan. We analyze the strategy, financials, and what it means for investors.

With over AUD$1M in sales from its first MDMA batch, Cortexa is validating Australia's pioneering move to legalize psychedelic-assisted therapy.

The life sciences analytics provider earned a top sustainability rating, signaling a shift where ESG performance is now critical for pharma partnerships.

Sydnexis's eye drop trial shows high efficacy in children 3-12, positioning it as a potential first-of-its-kind FDA-approved drug for myopia.

The bioconjugate CRDMO reports record profits and a $1.49B backlog, fueled by tech innovation, strategic acquisitions, and global expansion.

Ephicacy appoints biometrics SVP Jamie Powers and India Head Tyagi Swaminathan in a strategic push to dominate advanced clinical trial analytics.

A key preclinical success in a $570M partnership advances a novel therapy designed to reset the immune system for patients with lupus, MS, and arthritis.

With key trial enrollment complete, Pyxis Oncology refines its cancer drug MICVO for safety and prepares for pivotal data under a new, seasoned CEO.

A major chemical firm is raising prices, revealing how Red Sea disruptions and market volatility directly impact costs for pharma, personal care, and more.

With a new grant, Tessera Therapeutics is advancing its novel Gene Writing platform to engineer a scalable, single-shot cure for HIV. But can it work?

With major expansions in the US and Europe, Cambrex aims to lead the high-stakes race for specialized API production, targeting next-generation therapies.

A major labor dispute at the world's top drug manufacturer threatens global supply chains, with a union pointing to deep-seated governance issues at Samsung.

With a promising non-opioid drug and new leadership known for major deals, Persica Pharmaceuticals is poised to revolutionize back pain treatment.

UK biotech Amphista to showcase its innovative Targeted Glue™ platform at AACR, revealing new data for AML, lung cancer, and mesothelioma therapies.

A top university and a global clinical research firm unite to slash drug development timelines, aiming to bring innovative therapies to patients faster.

With 17 abstracts at AAD 2026, LEO Pharma showcases real-world data to tackle treatment gaps in diverse populations and chronic skin diseases.